AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

The announcement by AstroZeneca follows a growing trend of companies pledging to invest in pharmaceutical manufacturing on American soil in pursuit of appeasing President Donald Trump as he threatens ...